Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis.

Krishnan B, Smith TL, Dubey P, Zapadka ME, Torti FM, Willingham MC, Tallant EA, Gallagher PE.

Prostate. 2013 Jan;73(1):71-82. doi: 10.1002/pros.22542.

2.

Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1.

Krishnan B, Torti FM, Gallagher PE, Tallant EA.

Prostate. 2013 Jan;73(1):60-70. doi: 10.1002/pros.22540.

PMID:
22644934
3.

Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.

Lee YP, Schwarz EM, Davies M, Jo M, Gates J, Zhang X, Wu J, Lieberman JR.

Cancer Res. 2002 Oct 1;62(19):5564-70.

4.

Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2.

Menon J, Soto-Pantoja DR, Callahan MF, Cline JM, Ferrario CM, Tallant EA, Gallagher PE.

Cancer Res. 2007 Mar 15;67(6):2809-15.

5.

Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor.

Soto-Pantoja DR, Menon J, Gallagher PE, Tallant EA.

Mol Cancer Ther. 2009 Jun;8(6):1676-83. doi: 10.1158/1535-7163.MCT-09-0161.

6.

Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis.

Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B, Bhagat S, Mullins C, Fridman R, Cher ML.

J Natl Cancer Inst. 2002 Jan 2;94(1):17-25.

7.

Curcumin analogue UBS109 prevents bone loss in breast cancer bone metastasis mouse model: involvement in osteoblastogenesis and osteoclastogenesis.

Yamaguchi M, Zhu S, Zhang S, Wu D, Moore TM, Snyder JP, Shoji M.

Cell Tissue Res. 2014 Jul;357(1):245-52. doi: 10.1007/s00441-014-1846-4.

PMID:
24723227
8.

Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.

Magnusson LU, Hagberg Thulin M, Plas P, Olsson A, Damber JE, Welén K.

Prostate. 2016 Mar;76(4):383-93. doi: 10.1002/pros.23133.

PMID:
26660725
9.

EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells.

Bhatia V, Saini MK, Shen X, Bi LX, Qiu S, Weigel NL, Falzon M.

Mol Cancer Ther. 2009 Jul;8(7):1787-98. doi: 10.1158/1535-7163.MCT-09-0064.

10.
11.

Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.

Mohamedali KA, Li ZG, Starbuck MW, Wan X, Yang J, Kim S, Zhang W, Rosenblum MG, Navone NM.

Clin Cancer Res. 2011 Apr 15;17(8):2328-38. doi: 10.1158/1078-0432.CCR-10-2943.

12.

Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.

Nemeth JA, Harb JF, Barroso U Jr, He Z, Grignon DJ, Cher ML.

Cancer Res. 1999 Apr 15;59(8):1987-93.

13.

Angiotensin-(1-7) Decreases Cell Growth and Angiogenesis of Human Nasopharyngeal Carcinoma Xenografts.

Pei N, Wan R, Chen X, Li A, Zhang Y, Li J, Du H, Chen B, Wei W, Qi Y, Zhang Y, Katovich MJ, Sumners C, Zheng H, Li H.

Mol Cancer Ther. 2016 Jan;15(1):37-47. doi: 10.1158/1535-7163.MCT-14-0981.

14.

Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.

Feeley BT, Krenek L, Liu N, Hsu WK, Gamradt SC, Schwarz EM, Huard J, Lieberman JR.

Bone. 2006 Feb;38(2):154-66.

PMID:
16126463
15.

Inhibition of human lung cancer cell growth by angiotensin-(1-7).

Gallagher PE, Tallant EA.

Carcinogenesis. 2004 Nov;25(11):2045-52.

16.

Targeting of α(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer.

van der Horst G, van den Hoogen C, Buijs JT, Cheung H, Bloys H, Pelger RC, Lorenzon G, Heckmann B, Feyen J, Pujuguet P, Blanque R, Clément-Lacroix P, van der Pluijm G.

Neoplasia. 2011 Jun;13(6):516-25.

17.
18.

Bone-specific growth inhibition of prostate cancer metastasis by atrasentan.

Drake JM, Danke JR, Henry MD.

Cancer Biol Ther. 2010 Apr 15;9(8):607-14.

PMID:
20139704
19.

Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.

Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri DC, Pratap J, Keller E, Stein GS, Lian JB.

Oncogene. 2010 Feb 11;29(6):811-21. doi: 10.1038/onc.2009.389.

20.

Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.

Yonou H, Kanomata N, Goya M, Kamijo T, Yokose T, Hasebe T, Nagai K, Hatano T, Ogawa Y, Ochiai A.

Cancer Res. 2003 May 1;63(9):2096-102.

Items per page

Supplemental Content

Support Center